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ABSTRACT 
Objective: The study was designed to prepare Nano-sponge formulation loaded with nifedipine. Studying parameters which affecting the formulas 
in addition to pharmacokinetics and toxicity tests. 
Methods: Nine Nano-sponge formulations were prepared by the solvent evaporation technique. Different ratios of polymer ethylcellulose, CO-
polymers β-cyclodextrin and hydroxypropyl β-cyclodextrin in addition to solubilizing agent polyvinyl alcohol were used. Thermal analysis, X-ray 
powder diffraction (XRPD), shape and surface morphology, particle size, %production yield, %porosity, % swelling, and % drug entrapment 
efficiency of Nano-sponge were examined. Release kinetic also studied beside comparison of pharmacokinetic parameters of the optimum choice 
formula and marketed one in addition to Toxicological consideration. 
Results: Particle size in the range of 119.1 nm to 529 nm which were increased due to the increase in the concentration of polymer to the drug. 
Nano-sponge revealed porous, spherical nature. Increased in the drug/polymer molar ratios (1:1 to 1:3) may increase their % production yield 
ranged from 62.1% to 92.4%. The drug content of different formulations was in the range of 77.9% to 94.7%, and entrapment efficiency was in the 
range of 82.72 % to 96.63%. Drug released in controlled sustained pattern and followed Higuchi, s diffusion mechanism. Pharmacokinetic 
parameters of optimized formula showed significant higher maximum plasma drug concentration, area under plasma concentration-time curve, 
volume of distribution and mean residence time. Nano-sponge loaded drug proved biological safety at low concentrations.  
Conclusion: Nano-sponge drug delivery system has showed small Nano size, porous with controlled drug release and significant-high plasma drug 
concentration that improved solubility, drug bioavailability and proved safety.  
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Nano-sponge is novel class of hyper-cross linked polymer-based 
colloidal structures consisting of solid nanoparticles with colloidal 
sizes and Nanosized cavities. They enhance stability, reduce side 
effects and modify drug release. The outer surface is typically 
porous, allowing sustain release of drug [1]. Nano-sponge is small 
spherical particles with large porous surface. Nano-sponge can 
significantly reduce the irritation of drugs without reducing their 
efficacy. The size of the Nano-sponge ranges in diameter from 250 
nm to 1μm [2]. These particles are capable of carrying both 
lipophilic and hydrophilic substances and of improving the solubility 
of poor water-soluble molecules [3]. Nano-sponge is encapsulating 
type of nanoparticles which encapsulates the drug molecules within 
its core [4]. They can be used for targeting drugs to specific sites, to 
release the drug in a controlled and predictable manner [5]. It is 
possible to control the size of Nano-sponge by varying the portion of 
cross-linkers and polymers. This technology is five times more 
effective at delivering drugs for breast cancer than conventional 
methods [6]. Nano-sponge are non-irritating, non-mutagenic, no 
allergenic and non-toxic [7]. They are solid in nature and can be 
formulated as oral, parenteral, topical or inhalational dosage forms 
[8, 9]. Topical Nano-sponge can be more patient compliant and 
provide sufficient patient benefits by reducing repeated doses and 
side effects [10]. Nifedipine is chemically known as dimethyl-1, 4-
dihydro-2, 6-dimethyl-4-(2-nitrophenyl) pyridine-3, 5 dicarboxylate 
(fig. 1A). It is pharmacologically a selective L-type calcium channel 
antagonist (Martindale the Extra Pharmacopoeia, 2002). It causes 
coronary vasodilation and increases coronary blood flow. It reduces 
the total peripheral vascular resistance, for which it is widely used in 
the treatment of hypertension, angina pectoris, various other 
cardiovascular disorders and Reynaud’s phenomenon [11]. Although 
calcium channels antagonists are still favored as primary treatment 
for older black patients and sub-lingual nifedipine has previously 
been used in hypertensive emergencies, it has a very low 
bioavailability, and it is photosensitive and thermally unstable. This 
compound, when exposed to daylight and certain wavelengths of 
artificial light readily converts to a nitrophenyl pyridine derivative 
(NFPD) (fig. 1B) [12]. Nifedipine is a commonly prescribed active 
ingredient for CVD. It is a highly non-polar compound, absorbed 
completely from the gastrointestinal tract, predominately from the 
Jejunum, but has a very low bioavailability mainly due to pre-
systemic metabolism. Following absorption, nifedipine is further 
metabolized in the small intestine and liver to more polar 
compounds which are primarily eliminated by the kidney [13]. 
Nifedipine is a photolabile compound, undergoing oxidative 
biotransformation in human body into pharmacologically inactive 
metabolites [14]. In the present study nifedipine was formulated as 
a Nano-sponge system helps to retain the drug for longer period and 




Fig. 1: Chemical structures of (A) Nifedipine (B) Nitro phenyl 
pyridine 
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MATERIALS AND METHODS 
Materials 
Nifedipine pure drug was kindly gifted from E. I. P. I. CO. Egyptian 
international Pharmaceutical Industries CO., Egypt. Polyvinyl alcohol 
(PVA; M. Wt. 22000 Da), dichloromethane and Ortho-phosphoric acid 
(Riedel-de Haën, Germany), were purchased from El-Shark al-Awsat 
Chemical Trading Company, Egypt. Ethylcellulose, β-cyclodextrin and 
hydroxypropyl β-cyclodextrin were purchased from Sigma–Aldrich, 
chemical Trade Company, Egypt, Hexane HPLC grade, Acetonitrile 
HPLC grade and Dichloromethane HPLC grade were purchased from 
(Merck, Darmstadt, Germany), water used all over the study was 
double distilled and of high purity. All other chemicals used are 
analytical grade and were used without further purification. 
Methods 
Preparation of nano-sponge by emulsion–solvent evaporation 
method 
Nano-sponge were prepared by emulsion solvent evaporation 
method using different proportions of ethyl cellulose as rate 
retarding polymer, co-polymers β-cyclodextrin and HP β-
cyclodextrin and solubilizing agent polyvinyl alcohol. Disperse phase 
consisting of nifedipine (20 mg) and requisite quantity of ethyl 
cellulose dissolved in 10 ml solvent (dichloromethane) was slowly 
added dropwise to a definite amount of PVA in 40 ml of aqueous 
continuous phase. PVA was alternated with each of β-cyclodextrin 
and HP β-cyclodextrin. The reaction mixture was stirred at 1000 
r/min for two h on a magnetic stirrer at 45 °C. The Nano-sponge 
formed were collected by centrifugation at 3000 r/min for 5 min 
through Nano-separation tube (Pall-USA), washed and were dried in 
air at room temperature. The dried Nano-sponge was stored in 
vacuum desiccator to ensure the removal of residual solvent, fig. 2. 
Formula optimization 
Nine different formulations were prepared with different ratios 
between ethylcellulose polymer and co-polymers β-cyclodextrin, HP 
β-cyclodextrin and solubilizing agent polyvinyl alcohol as shown in 
table 1. Each of drug concentration, volume of solvents, stirring 
speed and time also temperature were constant. 
Evaluation parameters 
Drug content uniformity 
The prepared Nano-sponge formulations of nifedipine were tested 
for their drug content. Powder of each dried formula was taken and 
triturated properly. Then a quantity of powder equivalent to 20 mg 
of drug was mixed with 20 ml phosphate buffer pH 6.8 and shaken 
properly in incubator shaker (IKA KS 4000 i Germany), at (160 
r/min) for 24 h at 37 °C. Then it was filtered through Whatman filter 
paper size 41, diluted to analyze for nifedipine content at λ max 235 
nm using U. V Spectrophotometer (Shimadzu-UV/800, Japan). 
 
Table 1: Formulation table of nifedipine loaded nano-sponge 
S. No. Ingredients F1 F2 F3  F4 F5 F6 F7 F8 F9 
1. Nifedipine (mg) 20 20 20 20 20 20 20 20 20 
2. Ethyl cellulose (mg) 10 20 30 10 20 30 10 20 30 
3. Polyvinyl alcohol (mg) 10 10 10 --- --- --- --- --- --- 
4. β-cyclodextrin (mg) --- --- --- 10 10 10 --- --- --- 
5. HPβ cyclodextrin (mg) -- --- --- --- --- --- 10 10 10 
6. Dichloromethane (ml) 10 10 10 10 10 10 10 10 10 
7. Distilled Water (ml) 40 40 40 40 40 40 40 40 40 
  
Differential scanning calorimetric (DSC) 
Thermal analysis was used in order to elucidate any interactions 
between drug, investigated polymer and Co-polymer. DSC was 
carried out using Shimadzu, DSC 60 thermal analyzer (Japan) with a 
liquid nitrogen cooling accessory. The analysis was performed under 
a purge of dry nitrogen gas (40 mL/ min−1). A sample of 2–5 mg was 
placed in an aluminum crucible cell and was firmly crimped with the 
lid to provide an adequate seal. The samples were heated from 
ambient temperature to 400 °Cat a preprogrammed heating rate of 
10 °C/ min−1. All samples either individual, physical mixture or 
loaded Nano-sponge were analyzed in the same manner. 
Fourier transform infra-red (FTIR) spectroscopy  
FTIR was used to study the molecular interaction between formulation 
components. The infrared spectrum of drug-loaded Nano-sponge 
sample was studied. FTIR spectra of ethylcellulose, β-cyclodextrin, 
pure drug, physical mixture and Nano-sponge were recorded by using 
an FT-IR spectrophotometer (Nexus 670, Nicolet, USA) in the region of 
400–4000 cm-1 with spectra resolution of 4 cm-1.  
X-ray powder diffraction 
X-ray diffracted peaks were obtained using the Philips X, Pert on 
powder diffraction coordination (Philips Analytical, the 
Netherlands) set with a directly set up goniometer in the Bragg-
Brentano focusing geometry. The X-ray generator was operated at 
40 KV and 40 mA, using the CuKα line at 1.54060 A as the radiation 
source. The samples were ground using a mortar and pestle. The 
crushed specimen was filled and arranged in a specimen holder 
made of aluminum. Samples were scanned from 4 ° to 90 ° (2θ) and 
in stage sizes of 0.0200, with count time of 0.7s, using an automatic 
divergence slit assembly with a proportional detector. The samples 
were scanned at 25 °C. Relative intensities were read from the strip 
charts and corrected to fix slit values. X-ray diffraction studies were 
conducted on pure drug, polymer, Co-polymer, physical mixture and 
optimized Nano-sponge formula.  
Optical microscopy 
A thin layer of aqueous colloidal dispersion was spread on a slide 
after dilution with a small drop of deionized water then dried. The 
nature of vesicles was observed and focused under a light 
microscope (Olympus, Philippines) at various magnification powers 
(10× and 40×). Photomicrographs were taken using Fujifilm Finepix 
F 40 fd (8.3 MP) digital camera with 3 × optical zooms.  
Particle size and polydispersity 
Particle size measurements of drug-loaded Nano-sponge were 
performed by Malvern Zeta sizer by dynamic light scattering (Nano ZS, 
Malvern, and Worcester-shire, UK). Before measurements samples 
were dispersed in distilled water. Three replicates were measured and 
values were presented as mean±standard deviation (SD). 
Zeta potential 
Zeta potential is a logical term for electrokinetic potential in 
colloidal dispersions and it is the most imperative parameter for 
physical stability of Nano-sponge. The higher the electrostatic 
repulsion between the particles more is the stability. 
Morphology and surface topography of nano-sponge  
The morphological features of prepared dried Nano-sponge were 
observed by scanning electron microscopy (SEM) at different 
magnifications (Hitachi-S 3400N, Japan) at the Center of Agriculture 
Researches, Cairo University. Also Transmission electron 
microscopy (TEM) HU-12A (Hitachi Ltd, Mito, Japan) at the Research 
Park of Faculty of Agriculture, Cairo University was used to 
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determine TEM size and shape of drug-loaded Nano-sponge. The 
samples were dispersed in distilled water before TEM technique.  
Entrapment efficiency 
The specified weight of Nano-sponge suspension was analyzed by 
dissolving the dry sample in 10 ml of distilled water. After drug was 
dissolved 10 ml of clear layer was taken and amount of drug in the 
water phase was detected by a UV-spectrophotometric method at λ 
max 235 nm. The test was repeated with another Nanoparticulate 
sample. The amount of drug encapsulated in Nano-sponge was 
analyzed by cooling centrifugation (Sigma, 3-30KS, Germany)for 30 
min at 15000 r/min and 4 °C and by measuring the concentration of 
drug in the clear supernatant layer by the UV-spectrophotometric 
method at λ max 235 nm. The test was again repeated with another 
sample. Drug concentration was determined with the help of 
calibration curve plotted in three different media (deionized water, 
0.1N HCl pH 1.2 and phosphate buffer pH 6.8). The amount of drug 
inside the particles was calculated by subtracting the amount of 
drug in the aqueous phase of the colloidal dispersion from the total 
amount of the drug in the Nano dispersed particles. The entrapment 
efficiency (%) of drug was calculated by the following equation. 
 
Loading efficiency  
The loading efficiency (%) of Nano-sponge can be determined by  
 
 ……. [15]. 
Production yield  
The production yield (PY) can be determined by calculating initial 
weight of raw materials used in the formulation and final weight of 
dried mass Nano-sponge [15].  
 
Porosity 
Porosity study was performed to check the extent of Nanochannels 
and Nano cavities formed [16]. The tapped and untapped (bulk) 
densities were determined by marking a small cuvette with known 
volume, then inserting a small known mass of powder into the 
cuvette (bulk density) and tapping it vertically against a padded 
benchtop 50 times (tapped density) [17]. The mass is divided by the 
initial and final volumes. True density was determined using ultra-
pycnometer 1000. True density was calculated by dividing the 
sample weight by the sample volume [18]. Owing to their porous 
nature, Nano-sponge exhibit higher porosity compared to the parent 
polymer and co-polymers used to fabricate the system. Percent 
porosity is given by equation [19].  
 
Swelling and water uptake 
Swell able polymers Nano-sponge and water uptake was determined 
by soaking three different weighable mass of each prepared Nano-
sponge formula in aqueous solvent for 72 h using graduated 
Eppendorf. Swelling and water uptake could be calculated using 
equations [19].  
 
 
In vitro drug release studies 
The in vitro release studies of drug-loaded Nano-sponge were 
carried out in USP type II auto sampler dissolution apparatus 
(Hansen, Germany) fitted with eight rotating paddle and vessels. 
Nine formulas were used for release study and the experiments 
were carried out in triplicate. The rotation speed was 100 r/min 
using 600 ml of 0.1N HCL (pH 1.2 buffer) for first 2 h and the 
remaining 24 h in phosphate buffer (pH 6.8), pH changed by adding 
of 30 gm of Trisodium orthophosphate [20] with sink conditions. 
Temperature of the dissolution medium was maintained at 37±0.5 
°C. At predetermined time intervals (0.5, 1, 1.5 and 2 h) in HCl pH 1.2 
and at (0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, 16, 18, 20, 22, and 24 h) in 
phosphate buffer pH 6.8, 2 ml sample was withdrawn and replaced 
with fresh dissolution media [21]. The samples were analyzed by the 
UV spectrophotometric method at λ max 235 nm and the results 
were reported. The absorbance of each sample was recorded and 
percentage drug release was calculated. Calibration curve of 
nifedipine in each pH media was used to calculate drug 
concentrations. 
Kinetic studies: mathematical models 
In the present study, data of the in vitro release were fitted to 
different equations and kinetic models in order to explain the 
release kinetics of nifedipine from Nano-sponge. The kinetic models 
used were Zero-order equation, First order, Higuchi release, Hixson-
Crowell, and Korsmeyer-Peppas models. The best fit with higher 
correlation (R2) was calculated. 
Zero-order kinetics 
Drug dissolution from pharmaceutical dosage forms that do not 
disaggregate and release the drug slowly, assuming that the area 
does not change and no equilibrium conditions are obtained, can be 
represented by the following equation:  
Qt = Qo+Kot  
Where Qt = amount of drug dissolved in time t,  
Qo = amount of drug in the dissolution,  
Ko = zero-order rate constant.  
When the data were plotted as % drug release versus time, if the 
plot is linear then data obeys zero-order kinetics with slope equal to 
Ko. This model represents an ideal release profile in order to achieve 
prolonged pharmacological action. 
First order kinetics 
To study the first order, release rate data were fitted to the following 
equation:  
Log Qt = Log Qo+K1 t/2.303 
Where Qt = amount of drug release in time t.  
Qo = initial amount of drug in solution.  
K1 = first-order release rate constant.  
When data were plotted as log cumulative % drug remaining verses 
time yields a straight line indicating that the release follows first-
order kinetics. The constant K can be obtained multiplying slope 
values. 
Higuchi model 
Higuchi developed several theoretical models to study the release of 
water-soluble and low soluble drugs incorporate in semisolids and 
or solid matrices. Mathematical expressions were obtained for drug 
particles dispersed in a uniform matrix behaving as the diffusion 
media.  
Q = KH-T1/2 
Where, Q = amount of drug at time t,  
KH = Higuchi rate constant.  
El-Assal et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 10, 47-63 
50 
When data were plotted according to this equation, i.e. cumulative 
drug released verses square root of time, yields a straight line, 
indicating that the drug was released by diffusion mechanism. 
Hixson-crowell model 
The release rate data were fitted to the following equation.  
Qo 1/3–Qt 1/=KHC t 
Where Qt = amount of drug release in time t,  
Qo = initial amount of drug in tablet,  
K H C = rate constant for Hixson-Crowell rate equation.  
Korsmeyer-peppas model 
To study this model the release rate data are fitted to the following 
equation.  
Mt/M ∞ = k t n 
Where Mt = amount of drug release at time t,  
M ∞ = amount of drug release after infinite time,  
Mt/M ∞ = factorial drug release % at time t,  
K= release constant,  
t= release time,  
n = Diffusional exponent for the drug release that is dependent on 
the slope of the matrix dosage forms. 
This is used when the release mechanism is not well known or when 
more than one type of release phenomenon could be involved [22]. 
In vivo drug absorption studies 
Study design 
The study was carried out to compare the pharmacokinetics of 
nifedipine in rabbit plasma following oral administration of Epilat® 
10 mg soft gelatin capsules (E. P. I. CO., EGYPT) and the best-
achieved drug entrapment efficiency percentage Nano-sponge (F5) 
using a non-blind, two-treatment, two-period, randomized, 
crossover design. The use and the treatment of rabbits in this study 
were conducted in full compliance with the spirit of Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC), 
International’s expectations for animal care and use ethics 
committees. The protocol of the study (REC-FPESPI-12/80) was 
approved by the Research Ethics Committee for experimental and 
clinical studies at the Faculty of Pharmaceutical Sciences and 
Pharmaceutical Industries, Future University in Egypt. 
Animals 
Six healthy albino male rabbits (weighing 2–2.5 kg) were housed in 
an air-conditioned room under controlled alternate day and night 
cycles; provided with artificial fluorescent light. The animals were 
fed standard pellet diet, water and libitum. These conditions were 
evaluated on a daily basis to ensure the safety and well-being of an 
animal. A veterinarian checked the health of animals to ensure the 
lack of clinically observable abnormalities. 
Administration of drug treatment to rabbits 
After overnight fasting, the rabbits randomly divided into two equal 
groups. Each rabbit of the first group was administered sample of 
drug-loaded Nano-sponge (F5) equivalent to 20 mg nifedipine (Test, 
treatment A) after dispersion in 10 ml distilled water. Meanwhile, 
the rabbits of the other group received conventional marketed 
Epilat® soft gelatin capsules after evacuation contained the same 
previous nifedipine dose (Reference, treatment B). Before 
withdrawal of blood samples, the marginal ear vein was dilated, 
using warm water and swapping with cotton, and then punctured 
(24 gauge needle) to allow withdrawal of blood samples (2 ml) at 0 
time (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 h (post-dose). 
The samples were collected in EDTA tubes to prevent blood 
coagulation, followed by centrifugation (3000 ×g) for 10 min to 
separate plasma. The samples were frozen in-20 °C refrigerator till 
analyzed. After 14 d washing up period, the test was repeated using 
cross over design. 
Chromatographic conditions 
HPLC; Parkin Elmer equipped with variable wavelength UV detector 
and autosampler, USA. The column used was C18, 250 mm × 4.6 mm, 
5μm Phenomenex kinetex. Acetonitrile: Water (60:30 v/v) used as 
mobile phase and pH was adjusted to 3.0 with orthophosphoric acid. 
The injection volume was 40 µl with Flow Rate 1 ml/min. The UV 
detector with variable wavelength adjusted at 235 nm. Winchrom 
was used as chromatographic data analysis program. 
Preparation of stock solutions 
Nifedipine standard stock solution was prepared by dissolving 10 
mg accurately weighed of pure drug in 100 ml of acetonitrile in 100-
ml-volumetric flask to obtain a concentration of 100 µg/ml 
nifedipine stock solution. The stock solution was diluted with 
acetonitrile to obtain working solutions ranging from 50-800 ng/ml. 
Diclofenac standard stock solution was prepared by dissolving 10 
mg accurately weighed of the compound in 100 ml of acetonitrile in 
100-ml-volumetric flask to obtain concentration of 100 µg/ml stock 
solution. Diclofenac stock solution was diluted with acetonitrile to 
obtain working solution of 100 ng/ml [23].  
Sample processing 
For calibration measurements, deep-frozen plasma was thawed at 
ambient temperature and 1 ml portions were pipette into centrifuge 
tubes covered with aluminum foil. 50 µ1of the calibration solutions 
and 200 µl of 1 M NaOH solution were added to the plasma and after 
mixing, 3 ml of the extraction solvent mixture (70%v/v n-
hexane+30%v/v dichloromethane) (30:70 v/v) was added. Following 
agitation on a vortex mixer for 30 s and centrifuging at 3000 r/min for 
15 min in the dark, 2 ml of the organic phase were transferred to a test 
tube covered with aluminum foil. The solvent was evaporated at 30 °C 
under a stream of high purity nitrogen using a test-tube thermostat. 
The residue was reconstituted in 200 µ1 of the mobile phase and 50 
µ1were injected into the chromatographic system. Samples 
evaporated to dryness were stored in a closed dark box until 
measured. The peak heights of nifedipine and the internal standard 
and the ratios of the peak heights were determined [24].  
For measurement of nifedipine in rabbit’s plasma samples, the 
frozen samples were thawed at ambient temperature and 200 µl of 1 
M NaOH solution were added to each plasma sample and after 
mixing, 3 ml of the extraction solvent mixture (70%v/v n-
hexane+30%v/v dichloromethane) (30:70 v/v) was added then the 
following steps were repeated as previously mentioned above [25]. 
Pharmacokinetic and statistical analyses 
The pharmacokinetic (PK) parameters following oral administration 
of both treatments for each animal in cross over design were 
estimated based on the non-compartmental analysis using residual 
method soft wear program. The estimated pharmacokinetic 
parameters included; Cmax (the maximum drug concentration; 
ng/ml), Tmax (the time to reach Cmax; h), AUC 0-48h (the area under the 
plasma concentration-time curve from zero to 48 h; ng h/ml), AUC0-
∞ (the area under the curve from zero to infinity; ng h/ml), t1/2 
(plasma elimination half-life; h), Kab (absorption rate constant; h-1), 
Kel (elimination rate constant; h-1), Vd (apparent distribution 
volume; L) and Tcl (total body clearance; ml/min) [26]. In addition to 
AUMC (area under the first-moment curve; ng h2/ml), MRT (mean 
residence time; h) and Cmax/AUC ratio; h-1. The results are expressed 
as mean values of six rabbit's±SD the statistical significance of the 
results was checked using one-way ANOVA Tukey compare test (MS-
DOS program) at a P-value of 0.05. 
Toxicological consideration; in vitro cytotoxicity 
Determination of sample cytotoxicity on cell culture (MTT 
protocol) 
A MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay was performed to determine the cytotoxic effects of 
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optimized Nano-sponge formula loaded with nifedipine on human 
normal kidney and liver cells were purchased from the ATCC 
(American Type Culture Collection, CCL-75™) [27]. A 96 well tissue 
culture plate was inoculated with 1 X 105cells/ml (100 ul/well) and 
incubated at 37°C for 24 h to develop a complete monolayer sheet. 
Growth medium was decanted from 96 well microtiter plates after 
confluent sheet of cells were formed, cell monolayer was washed 
twice with wash media. Two-fold dilutions of tested sample were 
made in RPMI medium with 2% serum (maintenance medium). 0.1 
ml of each dilution was tested in different wells leaving 3 wells as 
control, receiving only maintenance medium. Plate was incubated at 
37°C and examined. Cells were checked under inverted microscope 
for any physical signs of toxicity, e. g. partial or complete loss of the 
monolayer, rounding, shrinkage, or cell granulation. MTT solution 
was prepared (5 mg/ml in PBS) (BIO BASIC CANADA INC). 20ul MTT 
solution was added to each well. Plate Placed on a shaking table at 
150 r/min for 5 min, to thoroughly mix the MTT into the media then 
Incubation at 37 °C and 5% CO2 humidified atmosphere for 1-5 h to 
allow the MTT to be metabolized. The media Dumped off then the 
plate was dried on paper towels to remove any residue. Formazan 
(MTT metabolic product) was re-suspended in 200ul DMSO and 
placed on a shaking table at 150 r/min for 5 min, to thoroughly mix 
the formazan into the solvent. Optical densities (O. D) were read at 
560 nm using a multiwall microplate reader (Synergy HT, Biotech, 
France,) and subtract background at 620 nm. Optical density should 
be directly correlated with cell quantity. Half maximal inhibitory 
concentration IC50 was calculated for each cell type in addition to 
viability% and toxicity%. The experiment was performed in 
triplicate, and the result was expressed as mean±SD 
 
Toxicity % = 100-Viability % 
Hemolytic assay 
Hemolytic assay was carried out by adopting the method of Bulmus 
et al., 2003 [28]. Freshly collected human red blood cells were taken 
and washed three times by 150 mmol NaCl using centrifuge at 2500 
r/min for 10 min. The plasma was removed and the cells were 
suspended in phosphate buffer saline (pH 7.4) for made 2% RBCs 
concentration. Double folded dilutions concentrations (20000, 
10000, 5000, …., 0.61 μg/ml) of nifedipine Nano-sponge was mixed 
with 2% L of RBC solutions and the final reaction mixture volume 
was made up to 1 ml by adding sodium phosphate buffer. The 
reaction mixture was then placed in a water bath for 1 h at 37 °C. 
After the incubation time the reaction mixture was centrifuged again 
at 2500 r/min for 15 min. The supernatant was collected and the 
optical density was measured at 541 nm, keeping phosphate buffer 
saline as blank. Deionized water was used as a positive control. The 
experiment was done in triplicate and mean±SD was calculated. 
 
RESULTS AND DISCUSSION 
 
 
Fig. 2: Emulsion solvent evaporation technique 
 
Particle size analysis of nano-sponge  
The particle size distribution of the Nano-sponge was determined by 
Zeta sizer and the Nano-sponge were found to be uniform in size. 
Free-flowing powders with fine aesthetic attributes are possible to 
obtain by controlling the size of particles during polymerization. The 
average particle size of all formulations range from 119.1±137.6 nm 
to 529.0±33.38 nm as shown in table 2 which is in increasing order 
due to the increase in the concentration of polymer but it was 
observed that as the ratio of drug: polymer was increased, the 
particle size decreased. This could probably be due to the fact that at 
higher relative drug content, the amount of polymer available per 
Nano-sponge was comparatively less. Probably in high drug: 
polymer ratios less polymer amounts encapsulated the drug and 
reducing the thickness of polymer wall and Nano-sponge with 
smaller size was obtained. Probably emulsion of high surface area 
and small droplets size were formed with high stirring rate and 
Nano-sponge with smaller size were formulated. By performing the 
particle size analysis, it is concluded that the formulations had the 
particle size varies with the concentration of polymer to drug ratio. 
Polydispersity for formulas was ranged from 0.164±0.008 to 
0.293±0.018 indicating uniform particle size distributions and 
homogeneity of the prepared formulas. Zeta potential was negative 
sign and ranged from-9.8±3.38 to-28.8±0.283 mV ensure stability 
for longer period of time. Low potential values were observed for 
formulas prepared with PVA indicating steric hindrance 
stabilization, while high values were observed for formulas 
prepared with β-cyclodextrin and HP β-cyclodextrin pointed to 
electrostatic repulsive stabilization and prevention of particles 
aggregation [29]. 
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Table 2: Particle size of nifedipine Nano-sponge; (n=3) 
S. No. TEM size d. nm Malvern zeta sizer d. nm PDI Zeta potential mV 
F1 117.16±87.79 119.1±137.6 0.164±0.008 -9.8±3.38 
F2 149.08±90.02 308.1±62.58 0.293±0.018 -11.4±1.77 
F3 230.35±21.83 529.0±33.38 0.268±0.001 -12.3±1.06 
F4 94.76±22.27 165.3±12.51 0.281±0.024 -27.1±0.453 
F5 110.80±39.50 181.6±27.79 0.189±0.016 -25.2±1.10 
F6 170.61±11.51 279.3±38.42 0.259±0.008 -15.6±2.97 
F7 60.28±19.49 167.1±2.899 0.252±0.001 -28.8±0.283 
F8 95.79±33.97 248.7±6.788 0.289±0.033 -23.1±1.27 
F9 120.90±13.68 513.3±27.44 0.245±0.052 -22.0±1.34 
n= number of determination; mean±Standard Deviation 
 
Morphology determination by optical and electron microscopy  
The morphology of the Nano-sponge prepared by emulsion solvent 
evaporation technique was investigated by optical microscope, TEM 
and SEM. It was observed that the Nano-sponge were spherical, and 
uniform with smooth texture and no drug crystals on the surface as 
shown in fig. 3 by each of optical and Transmission electron 
microscope. SEM analysis showed that the Nano-sponge were 
uniformly spherical in shape with spongy and porous nature that 
cavities were clear in the center of spherical. Average particle size of 
Nano-sponge measured by TEM was found to be smaller than 
measuring with Zeta sizer which average ranged from 60.28±19.49 
nm to 230.35±21.83 nm. This is maybe attributed to the difference in 
the principles underlying these techniques. Thus Zeta sizer allowed 
the observation of Nano-sponge in a hydrated colloidal state. For TEM 
the sample was dried at 55 °C. Thus, particle sizes were recorded via 
different techniques were found to be in the following order TEM<Zeta 






    
    
(C) 
Fig. 3: (A) optical view of F5 Nano-sponge, (B) SEM image of F5 Nano-sponge, (c) TEM image of nine formulas in order starting from lift to 
right F1,F2,F3,F4,F5,F6,F7,F8 and F9 
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Percentage of drug content 
The percentage drug content of the formulated Nano-sponge (F1-F9) 
as shown in table 3 was found in the mean range from minimum 
77.99±0.24 % to maximum 94.75±0.43%. The percentage of drug 
content of formulation F1 was found to be 84.42±0.32%, 
formulation F2 was found to be 81.82±0.10%, formulation F3 was 
found to be 83.33±0.42%, formulation F4 was found to be 
83.22±0.02%, formulation F5 was found to be 94.75±0.43%, and 
formulation F6 was found to be 90.96±0.51%, formulation F7 was 
found to be 77.99±0.24%, formulation F8 was found to be 
86.17±0.07%, and F9 Formulation was found to be 87.31±0.13%. 
High percentage drug content proved high Nano-sponge capacity for 
drug encapsulation owing to porous polymeric nature. 
 
Table 3: Measurements of drug encapsulation characters; (n=3) 
S. No. EE% %Drug loading %Drug content 
F1 84.53±1.02 40.24±0.147 84.42±0.32 
F2 91.85±2.21 36.74±0.932 81.82±0.10 
F3 93.84±1.56 31.28±0.530 83.33±0.42 
F4 86.96±2.87 38.65±0.712 83.22±0.02 
F5 96.63±1.01 43.48±0.120 94.75±0.43 
F6 91.12±2.45 30.375±0.746 90.96±0.51 
F7 82.72±1.33 41.369±3.079 77.99±0.24 
F8 84.96±2.89 33.986±1.686 86.176±0.07 
F9 84.67±0.19 28.273±0.087 87.318±0.13 
 n= number of determination; mean±Standard Deviation 
 
Entrapment efficiency and drug loading  
The drug entrapment efficiency percentage of Nano-sponge 
formulations are given in table 3. The loading efficiency calculated 
for all formulas ranged from 43.48±0.120% w/w to 28.273±0.087% 
w/w presenting the highest loading efficiency was found for the F5 
formula where a greater amount of drug was encapsulated. The 
highest loading efficiency, greater the amount of drug was 
encapsulated. This could be attributed to the highest drug loading 
and optimum degree of cross-linking. The entrapment efficiency % 
was affected by drug: polymer molar ratios and changed when drug 
and polymer ratio has been changed. The entrapment efficiency of 
formulation F1 was found to be 84.53±1.02%, formulation F2 was 
found to be 91.85±2.21%, formulation F3 was found to be 
93.84±1.56%, formulation F4 was found to be 86.96±2.87%, 
formulation F5 was found to be 96.63±1.01%, and formulation F6 
was found to be 91.12±2.45%, formulation F7 was found to be 
82.72±1.33%, formulation F8 was found to be 84.96±2.89%, and F9 
was found to be 84.67±0.19%. Among all the formulations F5 
showed highest entrapment efficiency of 96.63±1.01%, while F7 had 
the lowest EE% of 82.72±1.33%. Drugs can be loaded into the Nano-
sponge cavities while they are in the solution state. Factors affecting 
drug loading and release from Nano-sponge have been well 
documented. The two important parameters investigated include 
the type and molar ratio of cross-linker used and the process of 
synthesis. The crystalline state of Nano-sponge varies with reaction 
conditions which further affects the amount of drug entrapment. 
Production yield, porosity and swelling 
The production yield is a measure of the accuracy of the technique, 
since it measures the actual weight of the prepared Nano-sponge 
(drug+polymer+co-polymer). This value was calculated by dividing 
the actual weight of the prepared Nano-sponge by the theoretical 
weight. The range of the production yield of the prepared Nano-
sponge was found to be between 62.1±0.92% and 92.4±0.48 % as 
shown in table 4. The highest value appeared in formula F5 
92.4±0.48 while the less value appeared in formula F9. It was 
observed that Increase in the drug/polymer molar ratios (1:1 to 1:3) 
affected and changed their yield and may increase due to the 
increase in the concentration of polymer. Tansel Comoglu, et al. [31] 
clarified in their study that the dispersion of the drug and polymer 
into the aqueous phase was found to be dependent on the agitation 
speed. As the speed was increased, the size of Nano-sponge was 
reduced and was found to be spherical and uniform. When the rate 
of stirring was increased up to 1000 r/min the spherical Nano-
sponge were formed with mean particle size of about 300 nm. They 
noted that at higher stirring rate the production yield was 
decreased. Possibly, at the higher stirring rates the polymer adhered 
to paddle due to the turbulence created within the external phase, 
and hence production yield decreased [32]. Bulk and tapped 
densities were measured for nine dried Nano-sponge formulas. Bulk 
densities ranged from 0.2240 g/cm3 to 0.3530 g/cm3. While the 
taped densities ranged from 0.2948 g/cm3to 0.4353 g/cm3. All 
formulas had a high percentage of porosity, swelling and water 
uptake due to spongy and porous nature. The Nano-sponge system 
has pores, that increase the rate of water uptake and hence 
solubilization of poorly soluble drug by entrapping such drugs in 
pores. Due to Nano size, surface area significantly increased and 
increase rate of solubilization of drugs having low solubility, and a 
dissolution rate-limited poor bioavailability [33]. Nano-sponge 
solubilize drug by possibly masking the hydrophobic groups, by 
increasing the wetting of the drug, and/or by decreasing the 
crystallinity of the drug [34]. β-Cyclodextrin cross-linking is a 
condensation polymerization reaction which requires region-selective 
addition of reagents, optimized reaction conditions and separation of 
product by efficient removal of by-products. Cyclodextrin is heated in 
solution with small molecules called cross-linkers that act like tiny 
grappling hooks to fasten different parts of the polymer together. The 
objective is to form spherically shaped particles filled with cavities 
where drug molecules can be incorporated and stored. The 
mechanism behind this reaction is nucleophilic attack at the OH-
groups by functionalities such as carbonate ion, azide ions, halide ions, 
thiols, thiourea, anhydrides and amines; this reaction requires 
activation of the oxygen atom by an electron-withdrawing group. 
Nano-sponge has been synthesized by substituting hydrogen of the 
primary hydroxyl groups present on the outer cavity of the parent β-
cyclodextrin, thus forming Nano-cavities for drug entrapment. 
Moreover, the Nanochannels which are formed due to cross-linking 




The thermograms (DSC) of drug, polymer, co-polymer, drug-
polymers physical mixture and Nano-sponge were presented in fig. 
4. The DSC curve of pure nifedipine showed a melting endothermic 
peak at 172.36 °C, while the physical mixture of drug and polymer 
exhibited an endothermic peak at 171.75 °C. Thus, by comparing the 
thermograms of drug and drug-polymer it was found that it has a 
suitable compatibility for further formulation. DSC thermogram of 
ethylcellulose showed an exothermic peak at 50.3 °C which was 
mainly due to the crystallization temperature of the sample. The 
second exothermic inflection was observed on higher temperature 
at 344.46 °C which can be attributed to thermal degradation of EC. 
The DSC of physical mixture, EC also displayed similar two 
exothermic peaks behavior, the first peak was due to crystallization 
temperature 85.06 °C and the second peak at 323.33 °C 
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corresponded to thermal decomposition of EC. The result showed 
increase in crystallization temperature by 40.86 % in EC. It is 
assumed here that the internal energy of treated EC atoms has 
altered, which caused change in crystallization temperature. DSC 
thermal analysis of β-cyclodextrine showed three exothermic peaks, 
first at 88.53 °C indicating dehydration, second at 113.55 °C around 
its melting point, third at 312.32 °C for decomposition of co-
polymer. In physical mixture degradation temperature was shifted 
to 290.15 °C, with 7% decrease in decomposition temperature. DSC 
of prepared Nano-sponge F5 showed that the melting peak of 
nifedipine disappeared. This indicated that nifedipine was dissolved 
and encapsulated within the polymer. The crystallization and 
decomposition temperature of EC appeared at 79.89 °C and 340.60 
°C respectively.  
The three peaks of β-cyclodextrine have appeared at 104.65 °C, 
239.81 °C and 301.79 °C indicating shift in the dehydration, melting 
and decomposition temperature. Thermal analysis of drug-loaded 
Nano-sponge showed decrease in the drugs crystallinity, higher 
thermodynamic energy, and enhancement of the amorphous 
property of the drug [37]. 
 
Table 4: Measurement of Nano-sponge characters; (n=3) 
S. No. %Production yield % Porosity % Swelling % Water uptake 
F1 82.5±0.23 0.727±0.007 150 306.25 
F2 70.0±0.56 0.747±0.005 133 365.71 
F3 80.0±0.18 0.760±0.011 112 250.00 
F4 87.2±1.36 0.737±0.014 125 192.30 
F5  92.4±0.48 0.781±0.001 125 217.85 
F6 90.3±0.87 0.728±0.008 150 333.33 
F7 65.5±0.77 0.758±0.011 180 365.38 
F8 78.2±0.15 0.726±0.006 150 200.29 
F9 62.1±0.92 0.775±0.008 128 444.44 
 n= number of determination; mean±Standard Deviation   
 
 
Fig. 4: DSC Thermogram of (a) Nifedipine, (b) EC (Ethyl cellulose), (c) β Cyclodextrine, (d) physical mixture, (e) Nanosponge formul 
 
FTIR 
FTIR spectra shown in fig. 5 envisaged the characteristic peaks of 
nifedipine at 3329.14 cm−1, 1681.93 cm−1 and 1226.73 cm−1 
represented that--NH stretching, C=O stretching and C--O bending 
groups of dihydropyridine. Same characteristic functional groups 
of nifedipine were appeared at 3329.14 cm−1, 1681.93 cm−1 and 
1226.73 cm−1 respectively in physical mixture with insignificant 
shifting of wave numbers. FT-IR of EC showed characteristic peaks 
at 2978.9 cm-1 and 2877.79 cm-1 due to C–H stretching vibration 
peak. The–OH stretching vibration peak was observed at 3479.58 
cm-1. The other important peaks at 1064.71 cm-1, and 1377.17 cm-1 
corresponded to C-O–C stretching and C–H bending respectively 
[38]. The FT-IR spectrum of physical mixture sample showed the 
same peaks for C–H stretching at 2978.9 cm-1, 2877.79 cm-1 and–
OH stretching peak was evidenced at 3441.01 cm-1. Vibration 
peaks at 1026.13 cm-1 and 1381.03 cm-1 were mainly due to C-O–C 
stretch and C–H bending, respectively. The result showed that C-O-
C stretch present in EC at 1064.71 cm-1 was shifted downward to 
1026.13 cm-1. The FTIR spectrum of β cyclodextrine showed a 
characteristic peak at 3645.46 cm−1 and 3583.74 cm−1–due to the 
O–H group stretching. An intense peak at 2927.94 cm−1 due to C–H 
asymmetric/symmetric stretching was also seen. In addition, a 
peak at 1635.64 cm−1 represented the H–O–H deformation bands 
of water present in β cyclodextrine. Peak at 1157.29 cm−1 
indicated C–H overtone stretching and another peak at 1029.99 
cm−1 indicated C–H, C–O stretching. As expected, all the FTIR 
spectra of the β cyclodextrine were identical with the physical 
mixture. All the sharp peaks belonging to β cyclodextrine and ethyl 
cellulose observed in physical mixture were the same in Nano 
formula. Thus, FTIR study of formulated Nano-sponge F5 
demonstrated that there were no chemical interactions articulated 
between drug and polymers used in the formulation as there were 
no chemical bonds established between nifedipine and carriers 
other than hydrogen bonding which was evidenced as change in 
the wavenumbers of FT-IR spectrum. 
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Fig. 5: FTIR Diagram of (a) Nifedipine, (b) EC (Ethyl cellulose), (c) β Cyclodextrine, (d) physical mixture, (e) Nano-sponge formula 
 
Powder X-ray diffractometers 
X-ray powder diffraction (XRPD) has been used for evaluating the 
crystallinity of Nano-sponge and its drug complexation capacity 
[39]. Changes in crystallinity have a profound effect on drug loading, 
solubility, dissolution and drug release kinetics. XRPD 
diffractograms of nifedipine, ethylcellulose, β cyclodextrin, physical 
mixture and nifedipine loaded Nano-sponge were illustrated in fig. 6 
in order to outline the different behavior between the 
experimentally obtained complexes, physical mixture and the 
simulated ones. The XRPD profile of nifedipine loaded Nano-sponge 
indicates that the material is low crystalline. Broad peaks in a 
diffractogram at around 11.8°, 19.6°, and 23.9° were observed. Pure 
nifedipine and individual polymers were in the crystalline state as 
known from sharp peaks. Decrease in the peaks intensity and 
baseline shift of diffractogram were observed due to presence of 
polymers in Nano-sponge when compared to the physical mixture of 
nifedipine along with ethylcellulose and β cyclodextrin. This might 
be due to decrease in crystalline of drug. EC showed peaks at 2θ 
equals to 11.04° and 20.31°, the XRPD of treated EC showed peaks at 
2θ equal to 12.25° and 22.28°. This clarified no significant change in 
XRPD pattern of treated EC with respect to control in addition to 
semi-crystalline nature of EC of each control and treated polymer. 
The diffractogram of the simple mixture was the sum of the spectral 
lines of both of the components that were present. However, the 
diffractogram of the β-CD complex exhibited the disappearance of 
some of the spectral lines at 2.96°, 3.56° and 4.94° (2θ). Additionally, 
the appearance of new lines was observed including weak lines at 
8.33°, 7.51° and 7.11° (2θ) and an intense line at 19.92 (2θ), 
indicating the presence of new solid crystalline phases that 
correspond to an inclusion complexes of the same nature. As it 
comes out from the XRPD pattern decomposition, some peaks occur 
in the crystalline Nano-sponge as well as in the nearly amorphous 
one, but their areas and, particularly, the intensity versus FWHM 
(Full Width at Half Maximum) ratio were clearly different, so 
outlining their different crystallinity. This indicates that a deep 
decrease occurs in the overall crystal quality as if the crystals 
transformed into amorphous state. However, this is not the case, 
since the broadening of the peaks can be reasonably related with an 
outstanding decrease in crystal size owing to the variation of some 
crystallization parameters. In fact, as evidenced in fig. 6, the XRPD 
pattern of the Nano-sponge Para crystalline phase can be generated 
from the convolution of the XRPD diagram recorded on the Nano-
sponge crystalline phase. Para-crystalline Nano-sponge showed high 
loading capacity with nifedipine, it may be supposed due to high 
cross-linking degree can be found between β-CD and EC. 
  
 
Fig. 6: X ray diagram of a) Nifedipine, (b) EC (Ethyl cellulose), (c) β Cyclodextrine, (d) physical mixture, (e) Nano-sponge formula 
 
In vitro drug release 
Fig. (7 a, b and c) showed plots of percent drug released as a 
function of time for different formulations, respectively. The total 
amount of drug released for the 1:1 of drug: polymer ratios were 
75.67% for F1, 90.21% for F4 and 85.60% for F7, observed at 
different time intervals for a period of 12 h. While the total amount 
of drug released for the 1:2 of drug: polymer ratios were 65.52%, 
75.46% and 71.43% for F2, F5 and F8 at 12 h respectively. At drug: 
polymer ratios 1: 3 the total amount of drug released at 12 h were 
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60.66%, 65.71% and 74.32% for F3, F6 and F9 respectively. At 20 h 
the total amount of drug released for drug: polymer molar ratios 1: 1 
were 90.51%, 100% and 98.87% for F1, F4 and F7 respectively. 
While the total released were 80.83%, 90% and 88.38% for F2, F5 
and F8 respectively at drug: polymer molar ratios 1:2. The total drug 
released at drug: polymer molar ratios 1:3 were 75.45%, 80.61% 
and 86.43% for F3, F6 and F9. It was observed that the release rate 
was related to drug: polymer ratio. Increase of drug release was 
observed as a function of drug: polymer ratio. The percent of drug 
released was decreased with an increase in the amount of polymer 
for all formulas. This may be due to the fact that the release of drug 
from the polymer matrix takes place after complete swelling of the 
polymer and as the amount of polymer in the formulation increased 
the time required to swell also increased. The release showed a bi-
phasic pattern with an initial burst effect may due to the drug 
present as non-inclusion complex in the external cavities. In the 
first-hour drug, the release was found to be ranged of 12% to 28%. 
In general, all Nano-sponge formulations showed a prolonged 
sustained and controlled release up to 24 h [40]. This release study 
could be attributed to highest drug loading and optimum degree of 
cross-linking. It has always been a challenge to control drug release 
in a predictable manner. Poorly-soluble drugs can be incorporated 
into Nano-sponge to increase their aqueous solubility by forming 
inclusion complexes. The poor solubility of Nano-sponge protects 
the entrapped drug from precipitation and agglomeration by 
preventing super saturation in the surrounding media. The drug is 
incorporated in such a way that the hydrophobic functionalities of 
the drug occupy the hydrophobic interior cavities of cyclodextrin 
units within the Nano-sponge while the hydrophilic groups present 
in the drug associate themselves with the hydrophilic external 
surface which remains exposed to the environment [41]. Judiciously 
loading active pharmaceutical ingredients into Nano-sponge ensures 
drug release in a pre-determined manner. Cross-linking Nano-
sponge provides Nano-cavities into which drugs could be loaded, 
followed by slow and gradual release. Drug release is dependent on 
degree of cross-linking and crystallinity. The net effect is 
enhancement in drug dissolution and consequent increase in drug 
bioavailability. Employing such systems guarantees optimal drug 
usage and patient compliance due to less frequency of 





Fig. 7: (a, b and c) % release of nine formulas of nano-sponge (M±SD) 
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Kinetic behavior  
The optimized formulation F5 had coefficient of determination (R2) 
values of 0.963, 0.932, 0.615, 0.992, 0.98 and 0.452 for Zero order, First 
order, second order, Higuchi, Hixon Crowell and n value of Korsmeyer 
Peppas respectively. A good linearity was observed with the Zero order, 
the slope of the regression line from Higuchi plot indicates the rate of 
drug release through the mode of diffusion and to further confirm the 
diffusion mechanism, data were fitted into the Korsmeyer Peppas 
equation which showed linearity for optimized formulation. Thus n 
value indicates the Fickian diffusion mechanism. Thus, the in vitro 
release kinetics of the optimized Formula was best fitted to Higuchi 
model equation which obeyed Fickian controlled diffusion mechanism. 
Also it was observed that most formulations as F1, F2, F3 and F6 
followed the same kinetic release behavior obeyed controlled diffusion 
as shown in table 5. In diffusion rate-limited release in addition to drug 
molecule, diffusion coefficient and length of diffusion path, sometimes 
effective surface area of drug with release medium are variables during 
the release process. For a complex system such as there are other factors 
influencing the release rate among which penetration rate of liquid into 
the system as hydration, swelling, relaxation, erosion and dissolution of 
polymer can be mentioned. The extents of liquid penetration and the 
polymer contributed properties are directly proportional to t1/2 and 
powered of t, respectively [42]. 
  
Table 5: Data fitting for nifedipine release from nano-sponge using the different kinetic model 














F1 0.93465  -0.93937 0.619651 0.980937 0.978862 0.979416 0.64906814 Non Fickian diffusion 
F2 0.96063  -0.95272 0.747903 0.990052 0.976991 0.959776 0.66319326 Non-Fickian diffusion 
F3 0.97011  -0.96779 0.834629 0.991079 0.981021 0.962395 0.60702618 Non Fickian diffusion 
F4 0.93192  -0.99722 0.877475 0.979332 0.991327 0.992458 0.42260813 Fickian diffusion 
F5 0.96315  -0.9327 0.615216 0.992797 0.981424 0.976247 0.45241417 Fickian diffusion 
F6 0.97801  -0.95569 0.773501 0.996163 0.982102 0.958582 0.58541112 Fickian diffusion 
F7 0.94432  -0.98259 0.850637 0.983286 0.9931 0.993772 0.46966562 Fickian diffusion 
F8 0.96548  -0.99840 0.971899 0.992114 0.993449 0.997399 0.46219493 Fickian diffusion 
F9 0.95151  -0.99395 0.985519 0.987181 0.984553 0.994819 0.47167783 Fickian diffusion 
n is the diffusional release exponent indicative of the operating release mechanism 
 
In vivo drug absorption study 
This study aimed to define the pharmacokinetics of nifedipine 
following oral administration of a new extended-release formulation 
F5 and conventional marketed formula after a single oral dose of 20 
mg nifedipine of each. Non compartmental pharmacokinetic 
parameters were then calculated. The corresponding mean±SD of 
pharmacokinetic parameters are listed in table 6. Plasma 
concentration-time curves of nifedipine after 20 mg single oral dose 
of the conventional and the slow release forms are shown in fig. 8. 
The results of one way ANOVA statistical analysis are clarified in 
table 7. The maximum plasma nifedipine concentration (Cmax) 
achieved by 20 mg of the slow release formula (F5) was significantly 
higher than that achieved by the same dose of the conventional 
formula (***p<0.001). There is no significant difference in time for 
maximum drug concentration (Tmax). The absorption rate constant 
(kab) of the conventional form was significantly higher than that of 
F5 (***p<0.001), consequently the absorption half-life (T1/2ab) was 
also higher (***p<0.001). The elimination rate constant (ke1) of the 
slow release form tends to be lower than that of the conventional 
form (***p<0.001), as a results the elimination half-life (T1/2el) was 
slower in in F5 (***p<0.001). F5 formula showed higher volume of 
distribution (Vd) (***p<0.001), slower total body clearance 
(***p<0.001), and approximately 3 fold higher in the area under 
plasma concentration-time curve (AUC0-48) (***p<0.001). Also each 
of area under first moment concentration-time curve (AUMC0-48) and 
the mean residence time (MRT) was significantly higher 
(***p<0.001). The maximum concentration (Cmax) is shown to reflect 
not only the rate but also the extent of absorption. Cmax is highly 
correlated with the area under the curve (AUC), contrasting blood 
concentration with time. Therefore, use of the Cmax/AUC ratio is 
recommended for assessing the equivalence absorption rates is 
independent of both intra-subject variation and possible differences 
in the extent of absorption and reflects only the contrast between 
the absorption and disposition rate constants (ka/k) [43]. The ratio 
was significantly higher in conventional form (***p<0.001) reflecting 
faster absorption rate. Comparing the pharmacokinetic parameters 
pointed to that nifedipine loaded Nano-sponge formula can be taken 
with reducing dose and/or frequency and as consequence side effect 
with increasing bioavailability. 
  
 
Fig. 8: Mean±SD plasma concentration profile for six albino rabbits obtained after oral administration of 20 mg nifedipine of optimum 
formula F5 and marketed nifedipine 
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Table 6: Mean±SD of pharmacokinetic parameters of marketed formula and F5 
Parameters Marketed formula F5 
Tmax (h) 3 3 
Cmax (ng/ml) 0.374±0.006 0.557±0.006 
Kab (h-1) 0.975±0.072 0.298±0.044 
T1/2ab (h) 0.712±0.050 2.357±0.370 
Kel (h-1) 0.287±0.011 0.081±0.003 
T1/2el (h) 2.416±0.092 8.552±0.408 
Vd (L) 30.672±0.942 50.501±3.526 
Tcl (ml/min) 146.669±4.296 68.384±7.149 
AUC0-48 (ng. h/ml) 1.887±0.062 4.615±0.107 
AUC48-∞ (ng. h/ml) 0.148±0.033 0.267±0.067 
AUC0-∞ (ng. h/ml) 2.035±0.085 4.882±0.174 
AUMC0-48 (ng. h2/ml) 7.786±0.338 54.542±3.668 
AUMC48-∞ (ng. h2/ml) 1.784±0.398 12.839±3.221 
AUMC0-∞ (ng. h2/ml) 9.571±0.688 67.381±6.867 
MRT(h) 4.697±0.163 13.779±0.901 
Cmax/AUC0-48 (h-1) 0.198±0.004 0.120±0.002 
 
Table 7: One way ANOVA statistical analysis of pharmacokinetic parameters 
Parameters Mean difference q P value 
Cmax (ng/ml) -0.1830 52.828 ***p<0.001 
Kab (h-1) 0.6770 18.310 ***p<0.001 
T1/2ab (h) -1.645 13.101 ***p<0.001 
Kel (h-1) 0.2060 39.008 ***p<0.001 
T1/2el (h) -6.136 42.985 ***p<0.001 
Vd (L) -19.829 15.782 ***p<0.001 
Tcl (ml/min) -3.251 45.812 ***p<0.001 
AUC0-48 (ng. h/ml) -2.728 59.160 ***p<0.001 
AUC48-∞ (ng. h/ml) -0.119 4.372 *p<0.05 
AUC0-∞ (ng. h/ml) -2.847 40.386 ***p<0.001 
AUMC0-48 (ng. h2/ml) -37.756 30.621 ***p<0.001 
AUMC48-∞ (g. h2/ml) -11.055 10.143 ***p<0.001 
AUMC0-∞ (ng. h2/ml) -57.810 25.006 ***p<0.001 
MRT(h) -9.082 29.296 ***p<0.001 
Cmax/AUC0-48 (h-1) 0.078 39.000 ***p<0.001 
q= studentized range distribution, p= probability 
 
In vitro cytotoxicity  
Numbers of cultured cells used in the experiment were 100,000 cell of 
each kidney (Vero) and liver (HepG2). MTT assay measures the cell 
metabolic activity, which is directly proportional to cell numbers [44]. 
The percentages of viable cells were determined in relation to the 
control cells fig. (9 A, B) and fig. (10 A, B). Cytotoxic effects of Nano-
sponge loaded drug on Vero and HepG2 cells proliferation, viability 
and IC50 were carried out by MTT cytotoxicity assay as shown in 
tables 8 and 9. Different diluted concentrations of the tested Nano-
sponge sample on cells viability were carried out starting from 1000 
µg/ml to 19.531µg/ml. At high concentrations, toxicity was clear by 
cycling and shrinkage of both Vero and HepG2 cells. For epithelial 
kidney cells at 1000 µg/ml concentration viability% was low (6.957%) 
and toxicity% was high (93.042%). For epithelial liver cells viability % 
was (11.024%) and toxicity% was (88.975%). With dilution, the 
viability % increased while the toxicity% decreased hence at 
concentration 39.06 µg/ml the viability% of Vero cells was (99.169%), 
the toxicity% was (0.830%). At concentration 19.531 µg/ml the 
viability% of HepG2 cells was (99.392%), toxicity% was (0.607%). 
Decrease in cell growth measured by IC50 was 107.754µg/ml for Vero 
cells while IC50 for HepG2 cells was 147.736 µg/ml. Due to small size 
of Nano-sponge and high cellular uptakes the toxicity was great at high 
concentration and decreased with dilution. Toxicity test with all 
previous tests proved high efficient Nano-sponge loaded drug in 
addition to safety increased with decreased concentration. Also 
relation the numbers of tested cells to the numbers of whole boy cells 
(average 70 Kg body weight) the toxicity decline, so it concludes that 
nifedipine loaded Nano-sponge safe to administer orally at low 
concentration.
  
Table 8: Cytotoxic effects of the nano-sponge loaded drug on vero cells 
ID Conc. ug/ml O. D. Mean O. D. ST. E Viability % Toxicity % IC50 
vero 1:2 0.325 0.323 0.315 0.321 0.003055 100 0 ug/ml 
 
1 
10000 0.02 0.026 0.021 0.022333 0.001856 6.957424714 93.04257529  
107.754 5000 0.024 0.023 0.021 0.022667 0.000882 7.061266874 92.93873313 
2500 0.025 0.025 0.024 0.024667 0.000333 7.684319834 92.31568017 
1250 0.026 0.031 0.032 0.029667 0.001856 9.241952233 90.75804777 
625 0.035 0.04 0.029 0.034667 0.00318 10.79958463 89.20041537 
312.5 0.056 0.067 0.082 0.068333 0.007535 21.28764278 78.71235722 
156.25 0.072 0.088 0.094 0.084667 0.006566 26.37590862 73.62409138 
78.125 0.167 0.182 0.173 0.174 0.004359 54.20560748 45.79439252 
39.062 0.314 0.328 0.313 0.318333 0.004842 99.16926272 0.830737279 
19.531 0.317 0.32 0.316 0.317667 0.001202 98.9615784 1.038421599 
El-Assal et al. 








Fig. 9: (A and B): Nano-sponge toxicity effect on epithelial kidney cells at different concentrations 
El-Assal et al. 








Fig. 10 (A and B): Nano-sponge toxicity effect on epithelial liver cells at different concentrations 
El-Assal et al. 
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Table 9: Cytotoxic effects of nano-sponge loaded drug on HepG2 cells 
ID Conc. ug/ml O. D. Mean O. D. ST. E Viability % Toxicity % IC50 
HepG2 1:2 0.386 0.394 0.372 0.384 0.006429 100 0 ug/ml 
 
1 
10000 0.035 0.052 0.04 0.042333 0.005044 11.02430556 88.97569444  
147.736 
 
5000 0.039 0.051 0.047 0.045667 0.003528 11.89236111 88.10763889 
2500 0.046 0.058 0.062 0.055333 0.004807 14.40972222 85.59027778 
1250 0.073 0.069 0.082 0.074667 0.003844 19.44444444 80.55555556 
625 0.106 0.117 0.108 0.110333 0.003383 28.73263889 71.26736111 
312.5 0.135 0.14 0.122 0.132333 0.005364 34.46180556 65.53819444 
156.25 0.184 0.195 0.17 0.183 0.007234 47.65625 52.34375 
78.125 0.286 0.294 0.27 0.283333 0.007055 73.78472222 26.21527778 
39.062 0.367 0.375 0.383 0.375 0.004619 97.65625 2.34375 
19.531 0.384 0.379 0.382 0.381667 0.001453 99.39236111 0.607638889 
 
Hemolytic activity 
For parenteral administration, the non-toxicity of the formulations is 
essential. To evaluate the safety of the nifedipine-loaded Nano-sponge, 
hemolytic activity of aqueous drug formula was screened against 
normal human erythrocytes [45]. Hemolytic activity is expressed in % 
hemolysis. It was exhibited low to mild hemolytic effect toward human 
erythrocytes. Result indicated that drug formula (at dose 5000 μg/ml) 
possess minimum hemolytic activity (3.5%) where (at dose 20,000 
μg/ml) possess highest hemolytic activity (48.2%) Hemolytic 
percentage was found to be increasing with an increase in 
concentration (table 10). At concentration 1250 µg/ml the amount of 
hemolysis was negligible (0.1%), thereafter Nano-sponge suspensions 
were non-hemolytic starting at concentration 625 µg/ml to 0.6 µg/ml. 
Nifedipine-loaded formulations also showed good tolerability with 
erythrocytes; indeed, the amount of hemolysis was negligible, being as 
much as 99.6–99.7% of erythrocytes intact after incubation with 
Nano-sponge optimum formulation. Optical microscopy studies 
confirmed the intactness of the blood cells after incubation with the 
Nano-sponge formulation thereby proving its safety (fig. 11, 12). Thus, 
the formulation might be considered suitable for parenteral 
administration at dose immediately below 5000 μg/ml. 
 
Table 10: In vitro hemolytic activities of nifedipine loaded Nano-sponge 
Nno-sponge drug Conc. (µg/ml) Absorbance (at 540 nm) Hemolytic activity % 
20000 1.06 48.2 
10000 0.181 8.2 
5000 0.076 3.5 
1250 0.002 0.1 
625 0.001 0.0 
312.5 0.001 0.0 
156.25 0.001 0.0 
78.125 0 0.0 
39.1 0.001 0.0 
19.5 0.001 0.0 
9.76 0 0.0 
4.88 0 0.0 
2.44 0 0.0 
1.22 0 0.0 
0.61 0 0.0 
 
 
Fig. 11: Hemolytic effect of nano-sponge on human erythrocytes at different concentrations 
 
 
Fig. 12: Erythrocyte stability after incubation with Nano-sponge formulation: (a) plain RBC,s, (b) complete hemolysis as control, (c) RBC,s 
after treatment with concentration 5000 µg/ml 
El-Assal et al. 
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CONCLUSION 
The Nano-sponge was prepared by the solvent evaporation method. 
Ingredients used were compatible and the drug was encapsulated in 
Para crystalline phase. F5 was the optimum formula, its particle size was 
181.6 nm; PDI 0.189, percentage entrapment efficiency was 96.63%, 
drug content 94.75% and drug released was 75.46 % in 12 h with 
sustained pattern. Thermal analysis indicated chemically stability. SEM 
and TEM photographs revealed the spherical nature of the Nano-sponge 
in all variations. The release kinetics of optimized formulation was best 
fitted into Higuchi model and showed zero-order drug release with 
fickian diffusion mechanism. One way ANOVA statistical analysis of 
pharmacokinetic parameters for F5 proved significantly higher in all 
parameters as Cmax (ng/ml), T1/2el (h), Vd (L), AUC0-48 (ng. h/ml), AUMC0-∞ 
(ng. h2/ml) and MRT(h) at ***p<0.001compared with conventional 
marketed formula. In vitro cytotoxicity experiments emphasized safety 
on both liver and kidney epithelial cells especially at low concentrations 
in addition to good tolerability with erythrocytes and hemolysis was 
negligible. Nano-sponge formulation thereby proved its safety and better 
bioavailability. 
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